Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Getting into inflammation
June 2020
SHARING OPTIONS:

FRAMINGHAM, Mass.—Clinical-stage biotech BERG kicked May off by announcing a newly established collaboration with Boehringer Ingelheim. The two companies have teamed up to explore inflammatory diseases and identify potential biological drivers and biomarkers. Financial terms for the agreement were not disclosed.
 
“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with BERG’s next-generation AI-driven, patient-biology capability,” Dr. Niven R. Narain, co-founder, president and CEO of BERG, stated in a press release regarding the deal. “Our intent is for BERG’s Interrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.